The Board of Directors of BOIRON, at its meeting of September 8, 2016, made up the half-year statutory and consolidated financial statements.
|in thousands of euros||2015||2016||Variation |
|Sales (1)||275,573||284,304||+3.2% (2)|
|Net income - group share||21,451||26,458||+23.3%|
|Cash flow (3)||48,726||54,483||+11.8%|
|Net cash position||145,534||188,428||+29.5%|
(1) The main information on the variation of the half-yearly sales were the subject of a financial statement on July 19, 2016 (http://www.boironfinance.com/Shareholders-and-investors-area/Financial-information/Regulated-information/Financial-statements).
(2) +4.8% at constant exchange rate (as defined in the half-year report).
(3) Before investment income, financing expenses and tax.
The operating income at June 30, 2016 increased by 14.7% in comparison to the first half-year of 2015, due to higher revenues and cost control.
The increase of the cash position at June 30, 2016 is of +29.5%.
Our Company still continues with the same determination the development of homeopathy in the world.
The half-year accounts were subjected to a limited review by statutory auditors. The half-year report including information on activities and results of the first half-year and the 2016 outlook was published in line with the provisions of Article 221-3 of the French Financial Market Authority [AMF]. It is available on the company's website (http://www.boironfinance.com/Shareholders-and-investors-area/Financial-information/Regulated-information/Annual-and-half-year-reports).
Our next update:
October 20, 2016: at market close, publication of quarterly sales and financial information as of September 30, 2016.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 188.8.131.52.43 - e-mail : [email protected]
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com